According to the company, the XO Cath microcatheter is designed to offer new levels of torque response, trackability, and embolic compatibility for better treatment delivery
XO Cath microcatheter has received FDA clearance for embolic agent delivery. (Credit: Thomas G. from Pixabay)
Transit Scientific has received clearance from the US Food and Drug Administration (FDA) for its XO Cath microcatheter intended for the precise delivery of a wide range of embolic agents during complex endovascular procedures.
According to the Utah-based medical device company, the next-generation XO Cath microcatheter is designed to offer new levels of torque response, trackability, and embolic compatibility for better treatment delivery.
The metal-alloy construction, which is non-tapered, is intended to provide precise and superior control over the placement of embolic material. This ensures the best possible outcomes in minimally invasive operations, the medical device firm said.
Transit Scientific chief operations officer Jennifer Arnold said: “This FDA clearance underscores our commitment to developing cutting-edge medical solutions that cater to the evolving needs of interventional radiologists.
“This innovative microcatheter technology represents a fusion of innovation, precision, and safety, addressing critical challenges in embolic delivery procedures.”
The FDA 510(k) clearance is for the XO Cath 2.6F Microcatheter with 0.027″ ID for use with standard 0.014″, 0.018″, and 0.021″ guidewires, as well as the XO Cath 2F Microcatheter with 0.021″ ID for use with standard guidewires.
For radial access procedures, both microcatheters come in working lengths of 90cm, 110cm, 130cm, 150cm, 175cm, and the class-leading 220cm. They are available in a straight or bern-shaped tip.
Tri-City Medical Center interventional radiologist Richard Saxon said: “This breakthrough technology could substantially improve the successful completion of embolic procedures.
“Its trackability, precision, and embolic compatibility features will likely make a significant difference in patient care.”
Transit Scientific is focused on developing solutions for vascular procedures. Its portfolio also includes XO Score and XO Cross platforms in addition to the XO CS Constrain, which is presently being developed for peripheral and coronary operations.
Additionally, the medical device firm has more than 20 issued and pending US and international patents.